Ardelyx (ARDX) Q3 2024 earnings summary

Executive summary

• Q3 2024 total revenue reached $98.2 million, up from $56.4 million in Q3 2023, driven by strong product sales of IBSRELA and XPHOZAH.

• IBSRELA net product sales were $40.6 million, up 15% sequentially and 82% year-over-year; XPHOZAH net product sales were $51.5 million, with no comparable revenue last year.

• Net loss for Q3 2024 was $0.8 million, or $(0.00) per share, compared to net income of $6.6 million in Q3 2023, reflecting higher operating expenses.

• Cash, cash equivalents, and short-term investments totaled $190.4 million as of September 30, 2024.

• The company is actively addressing Medicare coverage uncertainty for Xphozah through legislative, legal, and commercial strategies.

Financial highlights

• Q3 2024 total revenue was $98.2 million, up 74% year-over-year; nine-month revenue was $217.5 million, up 141%.

• IBSRELA Q3 2024 net sales: $40.6 million (Q3 2023: $22.3 million); XPHOZAH Q3 2024 net sales: $51.5 million.

• Cost of goods sold for Q3 2024 was $15.7 million, up 104% year-over-year; operating expenses were $80.3 million, up 94%.

• R&D expenses: $15.3 million, SG&A expenses: $65.0 million in Q3 2024.

• Net loss: $0.8 million, including $9.1 million share-based compensation and $1.9 million non-cash interest expense.

Outlook and guidance

• Full-year 2024 IBSRELA U.S. net product sales guidance narrowed to $145–$150 million.

• Continued growth expected in Q4 for both products, with further updates on guidance anticipated early next year.

• Management expects continued operating losses as commercialization and development investments continue.

• Available cash and investments are expected to fund operations for at least one year from September 30, 2024.